All In Biotech

Drug Trial Radar · NCT03836040

Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OASIS PEDIATRIC [EM])

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 457 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

457

Actual

Start

Jul 19, 2019

Primary completion

Nov 19, 2025

Study completion Nov 17, 2026

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
Collaborators
Novartis
First posted
Feb 11, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years) with episodic migraine. The study hypothesis is that in pediatric participants with episodic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).

Conditions

  • Migraine

Interventions

  • Erenumab Dose 1Drug

    Participants in the low body-weight group at day 1 and who are randomized to Dose Level 1 will receive this dose.

  • Erenumab Dose 2Drug

    Participants in the low body-weight group at day 1 who are randomized to Dose Level 2 and subjects in the high body-weight group at day 1 who are randomized to Dose Level 1 will receive this dose.

  • Erenumab Dose 3Drug

    Participants in the high body-weight group at day 1 who are randomized to Dose Level 2 will receive this dose.

  • PlaceboOther

    Placebo matching dose for erenumab dose 1, 2 and 3.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in MMDsTime frame: Baseline through week 12 of the double blind treatment phase

Locations

11 sites in 4 countries. Site status is shown where the registry gives one.

  • Michigan Head Pain and Neurological Institute

    Ann Arbor, Michigan

  • Docteur Simona Sava

    Saint-Nicolas, Belgium

  • Servicios de Salud Ips Suramericana Sas - Ips Sura Industriales

    Medellín, Antioquia, Colombia

  • Institucion Prestadora de Servicios de Salud Sociedad Médica Rionegro SA Somer SA

    Rionegro, Antioquia, Colombia

  • Solano y Terront Servicios Medicos SAS - Unidad Integral de Endocrinologia Uniendo

    Bogota, Cundinamarca, Colombia

  • Fundacion Hospital Infantil Universitario De San Jose

    Bogota, Cundinamarca, Colombia

  • AthleticoMed

    Bydgoszcz, Poland

  • Uniwersytecki Szpital Kliniczny w Poznaniu

    Poznan, Poland

  • Clinical Research Center Spzoo Medic-R Spolka Komandytowa

    Poznan, Poland

  • Dr Sekowska Leczenie Bolu

    Warsaw, Poland

  • Migre Polskie Centrum Leczenia Migreny Anna Gryglas-Dworak

    Wroclaw, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.